Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -5.26% Market Closed
Market Cap: 189.3m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-20.2
Current
-3.4
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-20.2
=
Enterprise Value
176.4m AUD
/
EBIT
-8.7m AUD
All Countries
All Countries
Close
Market Cap EV/EBIT
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD -20.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
788.6B USD 60.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 28.7
US
Johnson & Johnson
NYSE:JNJ
384.8B USD 16.5
US
Merck & Co Inc
NYSE:MRK
259.4B USD 15.8
CH
Roche Holding AG
SIX:ROG
213.6B CHF 12.4
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 255.6
CH
Novartis AG
SIX:NOVN
183.5B CHF 15.4
US
Pfizer Inc
NYSE:PFE
160.4B USD 16.7

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-16.4
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A

See Also

Summary
ALA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALA stock valuation using valuation multiples.
Wall Street Estimates
ALA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 193,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.